New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
10:23 EDTVIAB, CMCSK, OHRP, SA, AERHigh option volume stocks: VIAB CMCSK OHRP SA AER
News For VIAB;CMCSK;OHRP;SA;AER From The Last 14 Days
Check below for free stories on VIAB;CMCSK;OHRP;SA;AER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
17:26 EDTOHRPOhr Pharmaceutical reports Q3 EPS (9c), one estimate (10c)
Subscribe for More Information
August 17, 2014
15:42 EDTVIABParamount's 'Ninja Turtles’ holds on to box office lead, Bloomberg says
Subscribe for More Information
August 14, 2014
17:00 EDTAERGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
14:13 EDTCMCSKOmega Advisors gives quarterly update on stakes
Subscribe for More Information
August 13, 2014
08:35 EDTOHRPOhr Pharmaceutical announces additional phase II data from IMPACT study
Ohr Pharmaceutical announced additional interim data from the Phase II study evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN versus placebo eye drops plus Lucentis PRN. Jason Slakter, MD, Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists. New data presented at ASRS showed that mean change in central subfield thickness was -139µm in the OHR-102 arm versus -117µm in the Lucentis monotherapy arm. Representative cases were shown at ASRS demonstrating that the combination of OHR-102 and Lucentis resulted in the resolution of sub-retinal hyper reflective material as well as intra-retinal and subretinal edema. There were no significant differences in the frequency of Lucentis PRN injections, which was the primary endpoint of the exploratory Phase II study. As announced previously, the mean number of Lucentis injections was 6.2 for the OHR-102 arm and 6.4 for the Lucentis monotherapy arm, which included the baseline injection and any injections required up to and including the final study visit for the interim analysis group. Squalamine eye drops were well tolerated and had a comparable safety profile to Lucentis monotherapy arm.
06:59 EDTAERAerCap has room to run folloiwng Q2 results, says UBS
Subscribe for More Information
August 12, 2014
07:02 EDTAERAerCap reports Q2 adj. EPS $1.29, consensus 79c
Reports Q2 revenue $806.8M, consensus $739.95M. The increase in adjusted EPS over Q2 of FY13 of 59c was driven primarily by the ILFC transaction.
August 11, 2014
15:32 EDTAERNotable companies reporting before tomorrow's open
Subscribe for More Information
August 10, 2014
17:04 EDTVIABParamount's 'Teenage Mutant Ninja Turtles' tops weekend box office, WSJ says
Paramount Pictures' (VIA,VIAB) "Teenage Mutant Ninja Turtles" edged out Disney's (DIS) "Guardians of the Galaxy," opening to an estimated $65M in the U.S. and Canada, says the Wall Street Journal. Reference Link
August 7, 2014
12:28 EDTVIABViacom ad, affiliate growth outlook still positive, says Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use